Fundraising Fox
/Companies
Sign in

Oncocyte

NASDAQ: IMDX

Irvine, US · California corporation

Find your way into Oncocyte

Sign up to see every warm intro you have to Oncocyte

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncocyte team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Insight Molecular Diagnostics (iMDx) develops molecular diagnostic tests for transplantation and oncology, including blood-based donor-derived cell-free DNA assays for transplant monitoring and gene-expression tests for cancer immunotherapy guidance. Its products serve researchers, clinicians, hospitals, and healthcare systems across clinical practice and translational research.

BiotechHealthtechMedical Devices

Founders & leadership

AJ
Andrea JamesChief Financial Officer
JL
James LiuSenior Director, Controller & Principal Accounting Officer
DT
Douglas T RossExecutive
PS
Padmavathi SundarExecutive
RA
Ronald A AndrewsExecutive
ML
Mitchell LevineExecutive
JRJosh Riggs
Josh RiggsCEO
JC
Johnson ChiangChief Technology Officer
ES
Ekkehard SchützChief Medical Officer, Europe & Managing Director of Chronix Biomedical GmbH

Board

AD
Alfred D KingsleyBoard director
AA
Andrew ArnoBoard director
AL
Andrew LastBoard director

Reported raises · per SEC filings

Form D private placements

$83M disclosed across 9 rounds · 2015–2025

▶$21.7MraisedFeb 2025 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Louis SilvermanDirector
  • Andrew LastDirector
  • Joshua RiggsExecutive Officer, Director
  • Andrea JamesExecutive Officer
  • James LiuExecutive Officer
  • Andrew ArnoDirector
Offering amount
$21.7M
Amount sold
$21.7M
First sale
Feb 2025
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.2MraisedOct 2024 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew ArnoDirector
  • Joshua RiggsExecutive Officer, Director
  • Andrew LastDirector
  • Andrea JamesExecutive Officer
  • James LiuExecutive Officer
  • Louis SilvermanDirector
Offering amount
$10.2M
Amount sold
$10.2M
Sales commissions
$250K
Placement agents
Needham & Company, LLC
First sale
Oct 2024
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.8MraisedApr 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joshua RiggsExecutive Officer, Director
  • James LiuExecutive Officer, Director
  • Louis SilvermanDirector
  • Andrew ArnoDirector
  • Alfred KingsleyDirector
  • Andrew LastDirector
Offering amount
$15.8M
Amount sold
$15.8M
Sales commissions
$250K
Placement agents
Needham & Company, LLC
First sale
Apr 2024
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedApr 2021 · 75 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas T RossExecutive Officer
  • Andy ArnoDirector
  • Melinda GriffithDirector
  • Padmavathi SundarExecutive Officer
  • Jennifer Levin CarterDirector
  • Ronald A AndrewsExecutive Officer, Director
  • Mitchell LevineExecutive Officer
  • Cavan RedmondDirector
  • Alfred D KingsleyDirector
  • Andrew J LastDirector
Offering amount
$17.5M
Amount sold
$3M
First sale
Apr 2021
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMar 2021 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cavan RedmondDirector
  • Melinda GriffithDirector
  • Alfred D KingsleyDirector
  • Mitchell LevineExecutive Officer
  • Padmavathi SundarExecutive Officer
  • Douglas T RossExecutive Officer
  • Jennifer Levin CarterDirector
  • Ronald A AndrewsExecutive Officer, Director
  • Andrew J LastDirector
  • Andy ArnoDirector
Offering amount
$5M
Amount sold
$5M
First sale
Feb 2021
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedFeb 2020 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew ArnoDirector
  • Cavan RedmondDirector
  • Alfred KingsleyDirector
  • Aditya MohantyDirector
  • Melinda GriffithDirector
  • Andrew LastDirector
  • Mitch LevineExecutive Officer
  • Ronald AndrewsExecutive Officer, Director
  • Albert ParkerExecutive Officer
Offering amount
$11M
Amount sold
$5M
First sale
Jan 2020
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.5MraisedSep 2016 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Russell SkibstedExecutive Officer
  • Don BaileyDirector
  • Cavan RedmondDirector
  • William AnnettExecutive Officer, Director
  • Andrew LastDirector
  • Aditya MohantyDirector
  • Alfred KingsleyDirector
  • Andrew ArnoDirector
Offering amount
$10.5M
Amount sold
$10.5M
Sales commissions
$511K
Placement agents
Cowen & Company, LLC
First sale
Aug 2016
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.3MraisedOct 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alfred D. KingsleyDirector
  • Cavan RedmondDirector
  • Kristine C. MechemExecutive Officer
  • Michael WestDirector
  • Robert W. PeabodyExecutive Officer, Director
  • Andrew ArnoDirector
  • William AnnettExecutive Officer, Director
  • Karen B. ChapmanExecutive Officer
  • Aditya MohantyDirector
Offering amount
$11.4M
Amount sold
$8.3M
Proceeds to insiders
$787.5K
First sale
Sep 2015
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Oncocyte do?
Insight Molecular Diagnostics (iMDx) develops molecular diagnostic tests for transplantation and oncology, including blood-based donor-derived cell-free DNA assays for transplant monitoring and gene-expression tests for cancer immunotherapy guidance. Its products serve researchers, clinicians, hospitals, and healthcare systems across clinical practice and translational research.
How much funding has Oncocyte raised?
Oncocyte has disclosed $83M raised across 9 rounds.
Where is Oncocyte headquartered?
Oncocyte is headquartered in Irvine, US.